智通财经APP获悉 ，平安证券发表研报称，BTK 抑制剂的问世是血液瘤治疗的重大突破，二代 BTK 抑制剂凭借更优疗效和安全性，市占率逐年提升。我国每年新发淋巴瘤患者10万人，虽然从发病率远低于一些实体瘤如肺癌，然而该领域靶向疗法的出现，使得临床治疗中淋巴瘤已然可视为慢病管理。患者基数及管理周期长叠加下，血液瘤领域相继出现多款突破十亿美元重磅分子如伊布替尼、泽布替尼、阿卡替尼、维奈克拉等，凸显出不 ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

BTK在自身免疫适应症的研发领域又迈出了新的一步。 9月2日，赛诺菲宣布，其BTK抑制剂托勒布替尼在HERCULES 3期研究中取得了积极结果，表明托勒布替 ...

During a Case-Based Roundtable® event, Andrew H. Lipsky, MD, moderated a discussion on the efficacy and safety of newer BTK ...

The BTK inhibitors market has experienced significant dynamics driven by advancements in oncology and autoimmune disease treatments. One of the primary drivers of the BTK inhibitors market is the ...

GlobalData’s report assesses the drugs in the Tyrosine Protein Kinase BTK pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

Initiated Phase 1b dose expansion of NX-5948 in chronic lymphocytic leukemia patient population with Fast Track Designation from the FDAInitiated ...

Exscientia plc (Nasdaq: EXAI) today announced three abstracts to be presented at the 36th EORTC-NCI-AACR (ENA) Symposium 2024 ...

Discover what crypto is and how it works. A cryptocurrency is a digital form of money. They are digital assets created to be used to pay for goods and services. Cryptocurrencies can be used as a ...

An abstract titled “NX-5948, a Clinical-Stage BTK Degrader ... Phase 1b expansion cohorts focused on patients with diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL).